Literature DB >> 6538112

Carcinogenesis in rats by nitrosodimethylamine and other nitrosomethylalkylamines at low doses.

W Lijinsky, M D Reuber.   

Abstract

Four nitrosomethylalkylamines were given to F344 rats in drinking water at concentrations of 0.22 mM or less. The total doses delivered to each animal were 0.5 and 0.2 mmol of nitrosodimethylamine (NDMA), 0.6 mmol of nitrosomethyl-2-oxopropylamine (NMOP) and nitrosomethyl-2-hydroxy-propylamine (NMHP) and 0.9 mmol of nitrosomethyl-2,3-dihydroxypropylamine (NMDHP). NDMA induced liver neoplasms in most of the animals, including 35% with hemangiosarcomas as well as hepatocellular tumors at the higher dose, but only hepatocellular tumors at the lower dose and the latter group of rats survived longer. NMOP induced a high incidence of esophageal tumors and NMHP induced a high incidence of both esophageal and nasal cavity tumors. NMDHP was the least potent of the 4 carcinogens, and induced lung tumors, neoplastic nodules in the liver, a few esophageal tumors and a few nasal cavity tumors, but after a long induction time.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6538112     DOI: 10.1016/0304-3835(84)90047-8

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  10 in total

Review 1.  Structure-activity relations in carcinogenesis by N-nitroso compounds.

Authors:  W Lijinsky
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

2.  Carcinogenesis by oxygenated nitrosomethylpropylamines in Syrian hamsters.

Authors:  W Lijinsky; R M Kovatch; G L Knutsen
Journal:  J Cancer Res Clin Oncol       Date:  1985       Impact factor: 4.553

3.  Temporal cell-type-specific mRNA expression of O6-methylguanine-DNA methyltransferases in liver of rats treated with dimethylnitrosamine.

Authors:  S Takahashi; J Hall; R Montesano
Journal:  Am J Pathol       Date:  1996-02       Impact factor: 4.307

4.  Species differences in nitrosamine carcinogenesis.

Authors:  W Lijinsky
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

5.  Ranitidine Use and Gastric Cancer Among Persons with Helicobacter pylori.

Authors:  Shria Kumar; David S Goldberg; David E Kaplan
Journal:  Dig Dis Sci       Date:  2021-04-15       Impact factor: 3.199

6.  Practical and Science-Based Strategy for Establishing Acceptable Intakes for Drug Product N-Nitrosamine Impurities.

Authors:  Krista L Dobo; Michelle O Kenyon; Olivier Dirat; Maria Engel; Andrew Fleetwood; Matthew Martin; Susan Mattano; Alyssa Musso; James Christopher McWilliams; Alexandros Papanikolaou; Patricia Parris; Jessica Whritenour; Shu Yu; Amit S Kalgutkar
Journal:  Chem Res Toxicol       Date:  2022-02-25       Impact factor: 3.739

7.  Pharmacoepidemiological Research on N-Nitrosodimethylamine-Contaminated Ranitidine Use and Long-Term Cancer Risk: A Population-Based Longitudinal Cohort Study.

Authors:  Chun-Hsiang Wang; I-I Chen; Chung-Hung Chen; Yuan-Tsung Tseng
Journal:  Int J Environ Res Public Health       Date:  2022-09-30       Impact factor: 4.614

8.  Risk of Cancer in Association with Ranitidine and Nizatidine vs Other H2 Blockers: Analysis of the Japan Medical Data Center Claims Database 2005-2018.

Authors:  Masao Iwagami; Ryosuke Kumazawa; Yoshihisa Miyamoto; Yuri Ito; Miho Ishimaru; Kojiro Morita; Shota Hamada; Nanako Tamiya; Hideo Yasunaga
Journal:  Drug Saf       Date:  2020-11-27       Impact factor: 5.606

9.  The induction of bladder tumors in F344 rats by intravesicular administration of some nitrosamines.

Authors:  B J Thomas; R M Kovatch; W Lijinsky
Journal:  Jpn J Cancer Res       Date:  1988-03

10.  Use of N-nitrosodimethylamine (NDMA) contaminated valsartan products and risk of cancer: Danish nationwide cohort study.

Authors:  Anton Pottegård; Kasper Bruun Kristensen; Martin Thomsen Ernst; Nanna Borup Johansen; Pierre Quartarolo; Jesper Hallas
Journal:  BMJ       Date:  2018-09-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.